Shots:

• The P-III METEORIC-HF study involves assessing of omecamtiv mecarbil (25/50 mg- bid) vs PBO in 270 patients in the ratio (2:1) on exercise capacity as determined by cardiopulmonary exercise testing (CPET) with HFrEF at sites throughout the US- Canada and EU
• In 2006- Amgen & Cytokinetics collaborated to develop therapeutics for the activation of cardiac sarcomere for heart failure. The second P-III METEORIC-HF Study is conducted by Cytokinetics in collaboration with Amgen and to be fund by Servier
• Omecamtiv Mecarbil is a cardiac muscle activator evaluated in global P-III GALACTIC-HF study versus PBO for patients with heart failure or have had a hospitalization or admission to an emergency room for heart failure within one year prior to screening

Ref: Amgen | Image: Twitter